DC
CNCE

Deere & Company’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Deere & Company’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-36,951
Closed -$505K – 1136
2016
Q1 		$505K Buy
36,951
+12,730
+53% +$183K 0.03% 593
2015
Q4 		$459K Buy
+24,221
New +$526K 0.03% 595

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deere & Company's CNCE Position: Q2 2016 in Review

Deere & Company sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2016, closing a stake of 36,951 shares — an estimated $505K sold.

Deere & Company first reported a position in CNCE in Q4 2015 and held it in 2 quarters. The position peaked at $505K in Q1 2016. 97 funds tracked by Wall St. Rank hold CNCE as of Q2 2016.

  • Deere & Company reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Deere & Company sold 36,951 Concert Pharmaceuticals, Inc. shares in Q2 2016, an estimated $505K.
  • Deere & Company first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Deere & Company's Concert Pharmaceuticals, Inc. position peaked at $505K in Q1 2016.
  • 97 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2016.

Based on Deere & Company's 13F filing for Q2 2016, filed 11 Aug 2016.